SLS - SELLAS Life Sciences Group, Inc.
IEX Last Trade
0.92
0.013 1.457%
Share volume: 1,190,446
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$0.91
-0.03
-0.03%
View ratios
| Fiscal Date | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2024-05-14 | 2024-08-13 | 2024-11-13 | |
| Total revenue | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | |||
| Operating expenses | 9.645 M | 7.621 M | 7.329 M | |
| Selling general and admin | 4.534 M | 2.435 M | 2.967 M | |
| Research and development | 5.111 M | 5.186 M | 4.362 M | |
| Total expenses | 9.645 M | 7.621 M | 7.329 M | |
| -20.98% | -3.83% | |||
| Operating income | -9.645 M | -7.621 M | -7.329 M | |
| Ebit | -9.645 M | -7.621 M | -7.329 M | |
| Pretax income | -9.566 M | -7.470 M | -7.108 M | |
| -21.91% | -4.85% | |||
| Income tax | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | |
| Net income | -9.566 M | -7.470 M | -7.108 M | |
| 21.91% | 4.85% |